TCT 2021 | OPTIMUM: Surgically Ineligible Patients with Complex Anatomy: Do We Accept the Case?

In surgically ineligible patients with complex coronary anatomy short term risk of death with PCI is considerably lower than the estimated surgical risk. These are the outcomes of the OPTIMUM registry, presented during the TCT scientific sessions. 

TCT 2021 | OPTIMUM: Anatomía compleja y no elegibles para cirugía ¿aceptamos el caso?

The good short-term outcomes highlight the importance of trying percutaneous revascularization to treat complex patients

The current data brought to us by the OPTIMUM results extremely useful, seeing as these patients have been systematically excluded from randomized studies in the last years. 

The OPTIMUM registry included 750 patients with multivessel or left main disease ruled out for surgery and therefore treated with PCI. 

This population was at high risk: 57% had diabetes, 48.2% prior MI, 32.8% prior revascularization and 16.4% prior surgery.

In addition, over one third had chronic kidney failure and 25% was in functional class III/IV.

Chronic total occlusions were fairly common, reaching almost 60%.

Mean Syntax score was 32.4, but nearly half scored >33 (45.3%).


Read also: TCT 2021 | iFR-SWEDEHEART: 5 Years to Trust FFR Is Equivalent to iFR.


At 30 days mortality resulted 5.6%, very similar to the estimated by STS with 5.3% and by EuroSCORE with 5.7%.

Between survivors at 6 months there was significantly improved quality of life and angina frequency. 

Original Title: Outcomes of percutaneous revascularization for the management of surgically ineligible patients with multivessel or left main coronary artery disease: primary results from the OPTIMUM registry.

Reference: Kandzari DE et al. Presentado en el congreso TCT 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...